There is no question that Sirtris Pharmaceuticals
A few weeks back, the company published a study in the scientific journal Cell showing promising results in its efforts to treat aging-related diseases. And just yesterday, the biopharmaceutical company reported positive preclinical results for its oral drug candidate aimed at treating eye disorders. At a meeting of the American Neurological Association, the company presented results demonstrating how its SRT501 drug was shown in an animal model to be beneficial in combating a disorder of the optic nerve that can cause a complete or partial loss of vision.
Investors in IPOs of small-cap companies such as Sirtris must be ready for volatility. But for Fools willing to take on a high degree of risk, the investments present an opportunity for tremendous upside potential. For example, China Shenghuo Pharmaceutical Holdings
Volatile or not, Sirtris has been selected to ring the opening bell for the Nasdaq this coming Tuesday. The recognition is well-deserved. The company has already been ringing in major-league gains for its shareholders in just its first five months of trading.
For related Foolishness check out:
Are you looking to improve the pipeline of stocks making it into your portfolio? Tom and David Gardner can help you achieve this with their market-beating Motley Fool Stock Advisor newsletter service. You can check out their recommendations with a 30-day free trial.
More from The Motley Fool
Will 2018 Be Canadian Solar Inc.'s Best Year Yet?
Canadian Solar's future is bright, but it may not be public long enough to show its true potential.
What Would Happen if Your Car Could Read Your Mind?
If it’s up to Nissan, we may soon find out.
How Axon Enterprise Can Become a Home Run Stock in 2018
If the taser and body camera company's management can get its finances in sync with its growth, this laggard could rapidly become a winning stock for investors.